HedgePath Pharmaceuticals (HPPI) Stock Price, News & Analysis

Company Overview

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.05 to $0.08
• 52-Week Range: $0.04 to $0.32
• Volume: N/A
• Average Volume: 19,283 shs
• Market Capitalization: $24.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HPPI Stock Analysis - Frequently Asked Questions

How have HPPI shares performed this year?

HedgePath Pharmaceuticals' stock was trading at $0.0601 on January 1st, 2025. Since then, HPPI stock has increased by 9.7% and is now trading at $0.0659.
View the best growth stocks for 2025 here.

How do I buy shares of HedgePath Pharmaceuticals?

Shares of HPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HedgePath Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HedgePath Pharmaceuticals investors own include Mesoblast (MESO), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Coca-Cola (KO), MSP Recovery (LIFW), MSP Recovery (LIFW) and Marathon Oil (MRO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:HPPI
• CUSIP: N/A
• CIK: 1042418
• Web: www.hedgepathpharma.com
• Phone: 813-509-2417
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,550,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -246.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.76
• Quick Ratio: 6.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -6.59

Miscellaneous

• Outstanding Shares: 370,446,000
• Free Float: N/A
• Market Cap: $24.42 million
• Optionable: Not Optionable
• Beta: -1.16